Sign in →

Test ID RAVU Ravulizumab, Serum

Ordering Guidance

To screen test complement abnormalities in the alternative pathway, order RAVUM / Ravulizumab Complement Blockage Monitoring, Serum.

Specimen Required

Patient Preparation: Natalizumab or eculizumab must be discontinued at least 4 weeks prior to testing for ravulizumab quantitation in serum.

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 2.5 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.

2. Centrifuge and aliquot serum into a plastic vial within 2 hours of collection.

Useful For

Assessing the response to ravulizumab therapy


Assessing the need for dose escalation


Evaluating the potential for dose de-escalation or discontinuation of therapy in remission states


Monitoring patients who need to be above a certain ravulizumab concentration in order to improve the odds of a clinical response for therapy optimization


This test is not useful as the sole basis for a diagnosis or treatment decisions.

Method Name

Liquid Chromatography-Tandem Mass Spectrometry, High Resolution Accurate Mass (LC-MS/MS HRAM)

Reporting Name

Ravulizumab, S

Specimen Type


Specimen Minimum Volume

1.1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reference Values

Lower limit of quantitation=5.0 mcg/mL


>175 mcg/mL-Therapeutic concentration for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
RAVU Ravulizumab, S 97184-6


Result ID Test Result Name Result LOINC Value
609420 Ravulizumab, S 97184-6

Day(s) Performed


Report Available

3 to 9 days